Nanoscope Therapeutics Inc.
Samir Gorasiya is a seasoned professional in quality control and pharmacology with a strong academic background, holding a PhD in Pharmacology from St. John's University. Currently serving as the Senior Manager of Quality Control at Nanoscope Therapeutics Inc. since December 2024, Samir has previously held significant positions at bluebird bio, including Senior Manager for QC Method Lifecycle Management & Strategy and Manager for QC Method Lifecycle Management. Prior experience includes roles at PPD as an Associate Group Leader and Senior Scientist, as well as graduate research roles and teaching positions at St. John's University and Long Island University. Samir's extensive skill set encompasses routine mammalian cell culture, in vivo experimentation, and mentoring, alongside practical experience in laboratory instruction and pharmaceutical market analysis.
This person is not in any teams
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa